Literature DB >> 10417629

Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180.

D Zillikens1, F Caux, J M Mascaro, U Wesselmann, E Schmidt, C Prost, J P Callen, E B Bröcker, L A Diaz, G J Giudice.   

Abstract

Lichen planus pemphigoides is an autoimmune subepidermal blistering disease. The finding of immunoglobulin G antibodies directed against the basement membrane zone differentiates it from bullous lichen planus. The aim of this study was to identify the target antigen of lichen planus pemphigoides autoantibodies. Sera from lichen planus pemphigoides patients (n = 4) stained the epidermal side of NaCl-split human skin in a pattern indistinguishable from that produced by bullous pemphigoid sera. In bullous pemphigoid, the autoimmune response is directed against BP180, a hemidesmosomal transmembrane collagenous glycoprotein. We previously demonstrated that bullous pemphigoid sera predominantly react with a set of four epitopes (MCW-0 through MCW-3) clustered within a 45 amino acid stretch of the major noncollagenous extracellular domain (NC16A) of BP180. By immunoblotting and enzyme-linked immunosorbent assay, lichen planus pemphigoides sera were also strongly reactive with recombinant bullous pemphigoid 180 NC16A. The lichen planus pemphigoides epitopes were further mapped using a series of overlapping recombinant segments of the NC16A domain. All lichen planus pemphigoides sera reacted with amino acids 46-59 of domain NC16A, a protein segment that was previously shown to be unreactive with bullous pemphigoid sera. Two lichen planus pemphigoides sera, in addition, reacted with the immunodominant antigenic region associated with bullous pemphigoid. In conclusion, there are now five bullous diseases that are associated with an autoimmune response to BP180: bullous pemphigoid; pemphigoid/herpes gestationis; cicatricial pemphigoid; linear immunoglobulin A disease; and lichen planus pemphigoides. In addition, we have identified a novel epitope within the BP180 NC16A domain, designated MCW-4, that appears to be uniquely recognized by sera from patients with lichen planus pemphigoides.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417629     DOI: 10.1046/j.1523-1747.1999.00618.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  [Involvement of mucous membranes in autoimmune bullous diseases].

Authors:  C Günther
Journal:  Hautarzt       Date:  2016-10       Impact factor: 0.751

Review 3.  The diagnosis and treatment of autoimmune blistering skin diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Dtsch Arztebl Int       Date:  2011-06-10       Impact factor: 5.594

4.  Narrowband UVB-induced lichen planus pemphigoide.

Authors:  Wai Man Mandy Chan; Joyce Siong See Lee; Colin Seng Thiam Theng; Sze Hon Chua; Hazel Hwee Boon Oon
Journal:  Dermatol Reports       Date:  2011-10-25

5.  Lichen Planus Pemphigoides Induced by Enalapril: A Case Report and a Review of Literature.

Authors:  Woranit Onprasert; Kumutnart Chanprapaph
Journal:  Case Rep Dermatol       Date:  2017-10-31

Review 6.  Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering.

Authors:  Franziska Hübner; Ewan A Langan; Andreas Recke
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

Review 7.  Serological Diagnosis of Autoimmune Bullous Skin Diseases.

Authors:  Sandra Saschenbrecker; Ingolf Karl; Lars Komorowski; Christian Probst; Cornelia Dähnrich; Kai Fechner; Winfried Stöcker; Wolfgang Schlumberger
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

Review 8.  Humoral Epitope Spreading in Autoimmune Bullous Diseases.

Authors:  Dario Didona; Giovanni Di Zenzo
Journal:  Front Immunol       Date:  2018-04-17       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.